Cargando…

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

OBJECTIVE: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy for inflammatory arthritis (IA). METHODS: This was a single-center, noninterventional, patient questionnaire-based study of adult IA patients currently receiving IV biologics. At a single visit, patients co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaylis, Norman B, Sagliani, Joanne, Black, Shawn, Tang, Kezhen L, DeHoratius, Raphael, Kafka, Wesley A, Parenti, Dennis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602473/ https://www.ncbi.nlm.nih.gov/pubmed/28979103 http://dx.doi.org/10.2147/PPA.S136567

Ejemplares similares

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic‐Naive Rheumatoid Arthritis Patients
por: Kottak, Nicholas, et al.
Publicado: (2018)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
por: Tesser, John, et al.
Publicado: (2019)

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab
por: Ellis, Lorie A, et al.
Publicado: (2019)

The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID
por: Gaylis, Norman B., et al.
Publicado: (2022)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
por: Dehoratius, Raphael J., et al.
Publicado: (2018)

Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study
por: Almalag, Haya M., et al.
Publicado: (2022)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

An estimate of the cost of administering intravenous biological agents in Spanish day hospitals
por: Nolla, Joan Miquel, et al.
Publicado: (2017)

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Machine Learning Applied to Patient‐Reported Outcomes to Classify Physician‐Derived Measures of Rheumatoid Arthritis Disease Activity
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

Accuracy of Potassium Supplementation of Fluids Administered Intravenously
por: Hoehne, S. N., et al.
Publicado: (2015)

Administration costs of intravenous biologic drugs for rheumatoid arthritis
por: Soini, Erkki J, et al.
Publicado: (2013)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
por: Mease, Philip, et al.
Publicado: (2020)

Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI
por: Peterfy, Charles G, et al.
Publicado: (2012)

Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study
por: Broadwell, Aaron, et al.
Publicado: (2023)

How do patients with inflammatory bowel disease want their biological therapy administered?
por: Allen, Patrick B, et al.
Publicado: (2010)

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study
por: Pritchard, Charles H, et al.
Publicado: (2014)

The intravenously administered palonosetron does not affect the spinal anesthesia
por: Kim, Myoung-Hun, et al.
Publicado: (2013)

In Vivo Toxicity of Intravenously Administered Silica and Silicon Nanoparticles
por: Ivanov, Sergey, et al.
Publicado: (2012)

Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19
por: Holman, Andrew J., et al.
Publicado: (2021)

Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
por: Bingham, Clifton O., et al.
Publicado: (2023)

MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
por: Brismar, Torkel B., et al.
Publicado: (2011)

Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis
por: Bolge, Susan C, et al.
Publicado: (2017)

Pharmacokinetic Behaviors of Intravenously Administered siRNA in Glandular Tissues
por: Huang, Yuanyu, et al.
Publicado: (2016)

Acute Toxicity of Intravenously Administered Titanium Dioxide Nanoparticles in Mice
por: Xu, Jiaying, et al.
Publicado: (2013)

Short-term biodistribution and clearance of intravenously administered silica nanoparticles
por: Waegeneers, Nadia, et al.
Publicado: (2018)

Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
por: Minnema, Jordi, et al.
Publicado: (2022)

Development of a self-administered early inflammatory arthritis detection tool
por: Bell, Mary J, et al.
Publicado: (2010)

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis
por: Pratt, Raymond D., et al.
Publicado: (2018)

Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
por: Calcanes, George, et al.
Publicado: (2019)

Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review
por: Walton, Gary D.
Publicado: (2019)

Use of clinical phenotypes to characterize emergency department patients administered intravenous opioids for acute pain
por: Caplan, Mordechai, et al.
Publicado: (2023)

Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932)
por: Peterfy, Charles G, et al.
Publicado: (2013)

Pharmacokinetics of Oral and Intravenous Paracetamol (Acetaminophen) When Co-Administered with Intravenous Morphine in Healthy Adult Subjects
por: Raffa, Robert B., et al.
Publicado: (2017)

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
por: Emery, Paul, et al.
Publicado: (2011)

Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
por: Hachulla, Eric, et al.
Publicado: (2018)

Intravenously administered cloxacillin-induced neutropenia with eosinophilia in a patient with infective endocarditis: a case report
por: Jayaweera, J. A. A. S., et al.
Publicado: (2018)

Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis
por: Migliore, Alberto, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t0pll29a1dupnlf3tagenlkts5